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Introduction
The suitability of active surveillance (AS) for African-American (AA) men with otherwise clinically favorable prostate cancer (PCa) at presentation has been questioned on the presumption of more aggressive disease. This assertion has been difficult to validate given marked under-representation of AA men in the landmark cohorts that have established the viability of surveillance in the low-risk state 1 2 . Indeed, AA men bear a comparatively greater burden from PCa relative to other major U.S. demographic groups, including increased PCa rates, higher proportions of high-grade and advanced-stage disease at presentation, and greater risk for cancer-specific mortality 3 4 5 . However, it is unclear whether these disparities persist following adjustment for disease characteristics, therapeutic selection, socio-economic status and access to care as conflicting studies addressing this issue exist 6 7 .
Among those studies that directly address outcomes of AA patients during AS, most indicate higher rates of disease reclassification and treatment compared with Caucasians, though are limited by smaller sample sizes and relative under-representation of AA patients within these cohorts 8 9 10 11 . In the absence of larger studies, concordance between clinical grade and stage with pathologic parameters at radical prostatectomy (RP) has been offered as a proxy for evaluating candidacy for AS in men with low-risk disease. Several studies with disproportionately low participation rates of AA men relative to the U.S. population have offered contrasting results: single institution and cross-sectional data from the National Cancer Database have shown higher rates of upgrading and upstaging, while others including a multi-institutional study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) showed no significant differences by race 12 13 14 15 . In this context, we sought to evaluate rates of pathological upgrading, upstaging, and recurrence-free survival among a racially diverse cohort M A N U S C R I P T
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of clinically low-risk men receiving surgical treatment for PCa within the United States Veterans
Affairs system, an equal access health system with a high representation of AA men.
Materials and Methods
Under 16 17 .
The primary study objective was to examine the effect of AA versus Caucasian race in occurrence of any adverse pathological characteristics among men with clinical low risk PCa treated with prostatectomy. We identified low-risk patients, defined as Gleason pattern ≤3+3 on diagnostic biopsy, PSA ≤10 ng/mL, and clinical stage ≤T2a. Men of other races, including missing or undefined responses, were excluded from analysis, as Asian, Latino, or Pacific
Islander status represented a small proportion of the cohort (n=46). Clinical and demographic characteristics were compared across AA and Caucasian strata using frequency tables, the Kruskall-Wallis, Wilcoxon, Mann-Whitney rank sum, chi-square t and t-tests as appropriate. We further described postoperative risk status using the Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score based on pre-treatment PSA and pathological characteristics 18 .
We examined several definitions of adverse pathology, including the presence of any
Gleason upgrade (≥3+4), major Gleason upgrade (≥4+3), upstage (≥ pT3a, or N1), or positive M A N U S C R I P T A C C E P T E D 
Results:
Clinical and Demographic Characteristics
We Hopkins criteria (63% and 38% of those with sufficient clinical data for calculation, respectively). The complete clinical and demographic characteristics are outlined in Table 1 .
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Pathological Findings
At radical prostatectomy, Gleason score was concordant with biopsy (3+3) in 523 (Table 3 ). In separate sub-set analyses of men meeting strict JHU (p=0.50) and UCSF strict AS criteria (p=0.75), AA status was not significantly associated with pathologic upgrade ≥3+4. Moreover, there was no significant association between AA versus Caucasian race and major pathologic upgrade, upstaging, or surgical margin status within these subsets (Table 4) .
Recurrence Free Survival
Among patients who did not experience BCR, the median follow-up was 6.3 years (IQR 3.8-8.9). Median follow was shorter for AA patients: 5.7 years (IQR 3.2-8.6) versus 6.6 (IQR M A N U S C R I P T 
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Discussion:
Whether or not AA men are at greater risk of adverse outcomes during surveillance for clinically low risk PCa is a matter of significant clinical importance. As AA men endure a higher burden of PCa in relation to Caucasian men, exclusion from AS will expose a considerable proportion of AA men to treatment and therefore warrants closer scrutiny 6 . Presently, discordance exists in the literature with some studies indicating higher risks of pathologic upstaging and biochemical recurrence among AA, while others showing equivalence when adjusting for relevant factors. Unifying limitations among these studies, however, are disproportionately low participation rates of AA patients and unmeasured influences of socioeconomic status and access to care 1, 12, 14 . We evaluated the role of AA versus Caucasian race within a large, diverse cohort of clinically low-risk men receiving treatment within six U.S.
Veteran's Affairs medical centers and observed no significant association between AA race and pathological upgrading, upstaging, positive margin status or biochemical recurrence following treatment. 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
steeper symphysis pubis angles and more narrow mid-pe lvic areas have been described that may impart greater technical challenge, particularly during apical dissection 26 27 .
Prior studies examining disparities in recurrence free survival outcomes among riskstratified AA men have demonstrated inconsistent results with several studies indicating an independent association of race and recurrence 1 28 . In this updated study restricted to low risk patients, we did not detect significant differences in the rates of clinical recurrence among AA men. Our findings are in agreement with an earlier SEARCH analysis examining pathologic outcomes among men who were candidates for AS-including 140 AA, comprising 42.5% of the cohort-where AA race was not significantly associated with time to BCR at median 43 month follow 29 . Our present results, within a restricted cohort of clinically low-risk men, are also consistent in direction with prior publications from the broader SEARCH experience, which have shown a small but consistently increased risk of recurrence in AA men in multivariable analysis that have not reached thresholds for statistical significance 17 30 . Greater statistical power may be required to definitively address this question within a longitudinally followed surgical cohort, however if present, such an effect would likely be small.
There are limitations of this analysis that require discussion. Improvements in biopsy with routine use of extended sextant sampling may not be well reflected among participants in earlier study years, factors that may exaggerate discordance between biopsy and prostatectomy.
To account for this, we adjusted for year of surgery in our analyses. In addition, we observed differences in the length of follow between AA and Caucasian participants of nearly one year, which introduces the possibility of follow up bias in our analysis of recurrence free survival. To address this, we used time to event analysis, which accounts for differential follow-up. In addition, pathologic specimens were not reviewed centrally, a limitation which may affect the M A N U S C R I P T
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relationship between biopsy and surgical pathologic assignment. Lastly, a subset of SEARCH participants were lacking complete clinical and demographic information, particularly among early study year participants. Such limitations also impacted the description of biopsy characteristics including the percentage of cores involved with tumor as well as the greatest single core tumor volume within treatment sites, variables that prevented the description of Johns
Hopkins University or UCSF strict criteria for approximately 40% of the study population.
We studied the role of AA versus Caucasian race on immediate pathologic and distant biochemical outcomes in a cohort of clinical low-risk men treated with prostatectomy. AA men were diagnosed at younger age and higher PSA, however when controlling for relevant disease characteristics, AA race was not independently associated with pathologic upgrading, upstaging, positive surgical margins or clinical recurrence. These findings may be directly impactful on the management of AA men with newly diagnosed PCa with low-risk features by demonstrating parity in surgical outcomes, which may offer a valuable surrogate inclusion criteria for AS candidacy. Ultimately, greater racial diversity within longitudinal surveillance cohorts is required to explicitly study the outcome of AA patients with favorable disease over time however these results support the validity of clinical risk stratification within AA men with localized PCa.
Conclusions:
Within a diverse, multi-centered multi-ethnic cohort of clinical low-risk men in an equal access medical system, African-American race was not associated with pathologic upgrading, PSA=prostate-specific antigen; AA=African-American *All models adjusted for treatment center M A N U S C R I P T 
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